{"title":"目前超说明书药物治疗在新型冠状病毒病(COVID-19)治疗中的应用","authors":"A. Pathan","doi":"10.37881/1.511","DOIUrl":null,"url":null,"abstract":"Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus, Severe acute respiratory syndrome SARS-CoV-2, that was first recognized in Wuhan, China, in December 2019. There are no FDA- approved therapeutics or drugs to treat, cure or prevent COVID-19. Some reported case studies indicated the significance of Chloroquine use in mild cases and Lopinavir and Ritonavir in severe cases of COVID-19 respectively. Indian Council of Medical Research, India issued a protocol which is to be implemented along with the WHO guidelines on clinical management of mild and severe acute respiratory infection when COVID-19 infection is suspected in Indian patients as a restricted public health emergency use.","PeriodicalId":383954,"journal":{"name":"NeuroPharmac Journal","volume":"7 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"Current off-label Pharmacotherapeutics in the management of novel coronavirus disease (COVID-19)\",\"authors\":\"A. Pathan\",\"doi\":\"10.37881/1.511\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus, Severe acute respiratory syndrome SARS-CoV-2, that was first recognized in Wuhan, China, in December 2019. There are no FDA- approved therapeutics or drugs to treat, cure or prevent COVID-19. Some reported case studies indicated the significance of Chloroquine use in mild cases and Lopinavir and Ritonavir in severe cases of COVID-19 respectively. Indian Council of Medical Research, India issued a protocol which is to be implemented along with the WHO guidelines on clinical management of mild and severe acute respiratory infection when COVID-19 infection is suspected in Indian patients as a restricted public health emergency use.\",\"PeriodicalId\":383954,\"journal\":{\"name\":\"NeuroPharmac Journal\",\"volume\":\"7 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-03-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NeuroPharmac Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.37881/1.511\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NeuroPharmac Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37881/1.511","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Current off-label Pharmacotherapeutics in the management of novel coronavirus disease (COVID-19)
Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus, Severe acute respiratory syndrome SARS-CoV-2, that was first recognized in Wuhan, China, in December 2019. There are no FDA- approved therapeutics or drugs to treat, cure or prevent COVID-19. Some reported case studies indicated the significance of Chloroquine use in mild cases and Lopinavir and Ritonavir in severe cases of COVID-19 respectively. Indian Council of Medical Research, India issued a protocol which is to be implemented along with the WHO guidelines on clinical management of mild and severe acute respiratory infection when COVID-19 infection is suspected in Indian patients as a restricted public health emergency use.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
